Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia

Biological Psychiatry

Volumn 54, Issue 6, 2003, Pages 587-598

  Fannon, Dominic ^a,d   Simmons, Andrew ^a   Tennakoon, Lakshika ^b   O'Céallaigh, Seamus ^a   Sumich, Alex ^a   Doku, Victor ^a   Shew, Carl ^a   Sharma, Tonmoy ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

^c NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antipsychotic; First episode; Hippocampus; MRS; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINE; CREATINE; CREATINE PHOSPHATE; HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADOLESCENT; ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; MALE; NEUROCHEMISTRY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BASAL GANGLIA; CASE-CONTROL STUDIES; CREATINE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; PHOSPHOCREATINE; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 0242380353     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00185-9     Document Type: Article

References (51)

1. Barr WB, Ashtari M, Bilder RM, Degreef G, Lieberman JA (1997): Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy. Br J Psychiatry 170:515-519.
2. Bartha R, al-Semaan YM, Williamson PC, Drost DJ, Malla AK, Carr TJ, et al (1999): A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry 45:1403-1411.
3. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, et al (1998a): Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 43:641-648.
4. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al (2001): The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49:39-46.
5. Bertolino A, Kumra S, Callicott JH, Mattay VS, Lestz RM, Jacobsen L, et al (1998b): Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry 155:1376-1383.
6. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al (1996): Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 153:1554-1563.
7. Buckley PF, Moore C, Long H, Larkin C, Thompson P, Mulvany F, et al (1994): 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol Psychiatry 36:792-800.
8. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, et al (1998): Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry 44:941-950.
9. Cecil KM, Lenkinski RE, Gur RE, Gur RC (1999): Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 20:131-140.
10. Choe BY, Suh TS, Shinn KS, Lee CW, Paik IH (1996): Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 31:345-352.
11. Cook MJ, Fish DR, Shorvon SD, Straughan K, Stevens JM (1992): Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 115:1001-1015.
12. Deakin JF, Simpson MD (1997): A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J Psychiatr Res 31:277-295.
13. Deicken RF, Johnson C, Eliaz Y, Schuff N (2000): Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiatry 157:644-647.
14. Deicken RF, Pegues M, Amend D (1999): Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr Res 37:217-223.
15. Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW (1997): Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am J Psychiatry 154:688-690.
16. Eastwood SL, Burnet PW, Harrison PJ (1995): Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66:309-319.
17. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA (2000): The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry 57:937-943.
18. Fannon D, Chitnis X, Doku V, Tennakoon L, O'Ceallaigh S, Soni W, et al (2000): Features of structural brain abnormality detected in first-episode psychosis. Am J Psychiatry 157:1829-1834.
19. First MB, Spitzer RL, Gibbon M, Williams JBW (1996): Structured Clinical Interview for DSM-IV Axis I Disorders-Non-Patient Edition (SCID-I/NP), version 2.0. New York: New York State Psychiatric Institute, Biometrics Research.
20. Fukuzako H, Takeuchi K, Hokanzono Y, Fukuzako T, Yamada K, Hashiguchi T, et al (1995): Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res 61:193-200.
21. Gothelf D, Soreni N, Nacham RP, Tyano S, Hiss Y, Reiner O, et al (2000): Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. Eur Neuropsychopharmacol 10:389-395.
22. Harris NG, Plant HD, Inglis BA, Briggs RW, Jones HC (1997): Neurochemical changes in the cerebral cortex of treated and untreated hydrocephalic rat pups quantified with in vitro 1H-NMR spectroscopy. J Neurochem 68:305-312.
23. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN (1998): Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res 83:105-115.
24. Her Majesty's Stationery Office (1991): Office of Population Censuses and Surveys: Classification of Occupations and Classification of Ethnicity. London: Her Majesty's Stationery Office.
25. Kay SR, Fiszbein A, Opler LA (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
26. Kegeles LS, Humaran TJ, Mann JJ (1998): In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry 44:382-398.
27. Keshavan MS, Montrose DM, Pierri JN, Dick EL, Rosenberg D, Talagala L (1997): Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Prog Neuropsychopharmacol Biol Psychiatry 21:1285-1295.
28. Maier M, Ron MA, Barker GJ, Tofts PS (1995): Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol Med 25:1201-1209.
29. Nasrallah HA, Skinner TE, Schmalbrock P, Robaitaille PM (1994): Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatry 165:481-485.
30. Oldfield RC (1971): The assessment and analysis of handedness: The Edinburgh Inventory. Neuropsychologia 9:97-113.
31. Peden CJ, Rutherford MA, Sargentoni J, Cox IJ, Bryant DJ, Dubowitz LM (1993): Proton spectroscopy of the neonatal brain following hypoxic-ischaemic injury. Dev Med Child Neurol 35:502-510.
32. Pettegrew JW, Keshavan MS, Panchalingam K, Strycher S, Kaplan DB, Tretta MG, et al (1991): Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48:563-568.
33. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan E, Lim KO (1999): In vivo spectroscopic quantification of the N-acetyl moiey, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 41:276-284.
34. Poland RE, Cloak C, Lutchmansingh PJ, McCracken JT, Chang L, Ernst T (1999): Brain N-acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. J Psychiatr Res 33:41-51.
35. Pouwels PJ, Brockmann K, Kruse B, Wilken B, Wick M, Hanefeld F, et al (1999): Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr Res 46:474-485.
36. Provencher SW (1993): Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679.
37. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, et al (1997): Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 41:837-843.
38. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM (1995): Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry 152:444-446.
39. Ritter LM, Meador-Woodruff JH (1997): Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression. Biol Psychiatry 42:155-164.
40. Sapolsky RM (2000): Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925-935.
41. Simmons A, Arridge SR, Barker GJ, Williams SC (1996): Simulation of MRI cluster plots and application to neurological segmentation. Magn Reson Imaging 14:73-92.
42. Simmons A, Smail M, Moore E, Williams SC (1998): Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn Reson Imaging 16:319-330.
43. Spitzer RL, Williams JBW, Gibbon M (1995): Structured Clinical Interview for DSM-IV (SCID). New York: New York State Psychiatric Institute, Biometrics Research.
44. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Mall A, et al (1996): An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 22:597-609.
45. Sugahara M, Shiraishi H (1998): Synaptic density of the prefrontal cortex regulated by dopamine instead of serotonin in rats. Brain Res 814:143-156.
46. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, et al (1992): Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530.
47. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al (1995): Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829-836.
48. Velakoulis D, Pantelis C, McGorry PD, Dudgeon P, Brewer W, Cook M, et al (1999): Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Arch Gen Psychiatry 56:133-141.
49. Webb PG, Sailasutu N, Kohler SJ, Raidy T, Moats RA, Hurd RE (1994): Automated single-voxel proton MRS: technical development and multi-site verification. Magn Reson Med 31:365-373.
50. Weinberger DR (1999): Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 45:395-402.
51. Yurgelun-Todd DA, Renshaw PF, Gruber SA, Ed M, Waternaux C, Cohen BM (1996): Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr Res 19:55-59.